Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

2 Leading Breast Cancer Researchers Discuss Emerging Anti-HER2 Therapeutics

March 1st 2012

Dennis Slamon, MD, PhD, and Carlos L. Arteaga, MD, discuss recent advances in anti-HER2 targeted therapies and the role of signaling by oncogenes.

Dr. Solin on Personalizing Treatment With the DCIS Score

February 28th 2012

Dr. Lawrence Solin from Einstein Medical Center on Personalizing Treatment With the DCIS Score

A Family Tradition: The Personal Story Behind the Miami Breast Cancer Conference

February 28th 2012

The Miami Breast Cancer Conference has become a well-respected and well-attended gathering that specialists make a point of returning to year after year.

Dr. Burris on Using Recurrence Scores to Predict pCR

February 23rd 2012

Dr. Howard Burris from Sarah Cannon Research Institute Discusses Recurrence Scores Predicting pCR

Dr. Perez Discusses Optimizing Adjuvant Therapy

February 22nd 2012

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses Optimizing Adjuvant Therapy

Dr. Schnabel on Predicting Breast Cancer by Atypia Type

February 21st 2012

Dr. Freya Schnabel from NYU School of Medicine on Predicting Breast Cancer by Atypia Type

Dr. Harvey on Aromatase Inhibitor Treatment Duration

February 20th 2012

Dr. Harold Harvey from Penn State Hershey Cancer Institute on Aromatase Inhibitor Treatment Duration

2 Landmark Trials Suggest Changes in Practice; Brachytherapy Controversy Attracts Attention

February 20th 2012

This commentary will highlight 2 phase III randomized trials and a retrospective review of a large national database that has been strongly criticized based on its overall conclusions.

Premature Tamoxifen Withdrawal Is Common in Male Patients With Breast Cancer

February 20th 2012

New data show that roughly one-fifth of tamoxifen-treated male patients with breast cancer stop treatment early because of side effects.

Dr. Bloom Explains Situations Requiring HER2 Retesting

February 16th 2012

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

Navigation Program Shows Limited Benefit in Underserved, Urban Women With Breast Cancer

February 15th 2012

The use of a navigation program for an urban safety net breast cancer population has only a moderate effect on the time from symptom presentation to treatment.

Breast Cancer is Diagnosed Later in Men but Is Less Often Fatal

February 14th 2012

New data show that while men are diagnosed with breast cancer at a mere fraction of the rate of women, they tend to have more advanced disease at the time of diagnosis.

Anastrozole Plus Fulvestrant Improved Survival in Metastatic Hormone Receptor-Positive Breast Cancer

February 13th 2012

The combination of anastrozole and fulvestrant improved survival when used as first-line therapy in postmenopausal women with metastatic HR-positive breast cancer compared with anastrozole alone.

Peripheral Neuropathy Profile More Favorable With Eribulin

February 10th 2012

Patients with metastatic breast cancer who were treated with eribulin mesylate were less likely to experience peripheral neuropathy.

Role of Bisphosphonate Therapy Refined but Still More Questions

February 9th 2012

The developing theme is that bisphosphonates are most effective in postmenopausal patients with HR-positive breast cancer.

FDA Updates: Pertuzumab Moves Forward, Denosumab Receives Setback

February 8th 2012

While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.

Dr. Burris Discusses the Stratification of Clinical Trials

February 8th 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Perez Describes Retesting Recurrent Breast Cancer

February 7th 2012

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Describes Retesting Recurrent Breast Cancer

Dr. Baselga on the Basis Behind the BOLERO-2 Trial

February 7th 2012

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Concurrent Zoledronic Acid Is Preferable in Letrozole-Treated Postmenopausal Patients With Breast Cancer

February 6th 2012

Upfront zoledronic acid is superior to delayed use in postmenopausal women with early breast cancer who are being treated with the aromatase inhibitor letrozole.